Q219 saw marginal revenue growth amid single-injection momentum and competitive pricing pressure
Among the many topics covered in the Q219 US Joint Fluid Market Recap* are:
- Market Highlights and Overview
- Single-Injection Arena: Off and Running - For Good?
- 3-Injection Arena: Overcrowding Continues
- 5-Injection Arena – Downward Spiral Continues…
The single-injection segment took over the market lead in Q219, with a commendable 46.9% share of the US Joint Fluid market, reflecting the general trend that the market is further migrating to the lowest treatment cycle according to some suppliers and product users. Meanwhile, 3-injection products dropped down to second place with...
*The entire article can only be viewed by SmartTRAK subscribers to this module. For information on how to subscribe, please click the button below.